The Marketplace model is winning: key insights from our webinar
The HealthVerity Marketplace webinar wrapped up with a clear message. The Marketplace model is not...
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically,...
The HealthVerity Marketplace webinar wrapped up with a clear message. The Marketplace model is not...
GLP-1 Trends: Ozempic and Semaglutide drive a 587% spike in prescriptions Prescriptions for GLP-1...
Prostate cancer is the most common cancer among men, aside from skin cancer, and is known for being...
FDA's AI guidance is reshaping real-world data standards Artificial Intelligence (AI) is rapidly...
Thank you to everyone who joined us at ISPOR 2025 in Montreal. Whether you stopped by our booth,...
Why data provenance matters for regulatory submissions and clinical trials Regulators increasingly...
This is part three of a three-part series on the essential qualities of claims data for life...
This is part two of a three-part series (read part 1, part 3) on the essential qualities of claims...
This is part one of a three-part series (read part 2, part 3) on the essential qualities of claims...
The problem with Zombie Data—And the critical need for Verified Data In life sciences, where...
In epidemiology, statistical power determines whether a study can accurately detect an effect of a given size with a specified probability, typically 80% or higher. When studies fall below that threshold, the consequences extend well beyond inconclus...